No more than  prior systemic treatment regimens for advanced PNET
Has received at least  prior regimens of standard treatment
Received =< four () prior chemotherapy regimens in the metastatic setting
Received ?  prior chemotherapy regimens and have relapsed or progressive disease as confirmed by radiologic assessment
UCC and SCCHN and salivary gland cancer - No more than three different prior treatment regimens in the advanced/metastatic setting with a maximum of two chemotherapy-containing regimens
Patients may have had up to  prior regimens for metastatic disease
Evidence of progressive disease during or following no more than  prior chemotherapy regimens
Receipt of more than  prior regimens of cytotoxic chemotherapy for metastatic disease unless prior approval is granted by the Sponsor.
Have previously received at least  but no more than  previous systemic regimens for the treatment of DLBCL
Part B) Combination Arm: HER-positive disease and received at least  prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting (not enrolling new patients);
Progressive disease after >=  prior chemotherapy regimens
Progressive disease after - prior chemotherapy regimens (perioperative chemotherapy within  months will be considered one regimen)
There is no limit to the number of prior chemotherapy regimens received; patients must have received at least one line of prior systemic chemotherapy for advanced unresectable and/or metastatic disease
Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after >  salvage regimens)
Having progressed on at least one prior line of therapy, histologically or cytologically confirmed diagnosis of one of the following: \r\n* Dose escalation and expansion cohorts:\r\n** Checkpoint inhibitor naive non-small cell lung cancer patients must have progressed on front-line therapy cytotoxic chemotherapy and may have received up to two prior treatment regimens provided no regimens included an anti-PD or PD-L agent or an oral VEGF TKI. Prior bevacizumab or ramucirumab is allowed.\r\n** Progressed on checkpoint inhibitor non-small cell lung cancer patients must have progressed on front-line checkpoint inhibitor therapy and may have received up to two prior treatment regimens provided no regimens included an oral VEGF TKI. Prior bevacizumab or ramucirumab is allowed.\r\n** Thymic carcinoma patients must not be eligible for surgical resection at the time of enrollment and may have received any number of prior lines of therapy provided no regimens included an anti-PD or PD-L agent or an oral VEGF TKI. Prior bevacizumab or ramucirumab is allowed.
Patients who received imatinib and  or  other TKIs as prior treatment regimens. Patients who experienced intolerance to prior therapies must have objective disease progression prior to enrollment onto BLU-- study.
Patients who have received more than  different prior TKI treatment regimens.
More than two prior cytotoxic chemotherapy regimens for the treatment of mCRPC
Part A patients who have received more than  prior cytoreductive chemotherapy regimens.
Patients must have had at least two prior chemotherapeutic or biologic (e.g. rituximab alone) regimens and not currently eligible for standard curative options; steroids alone and local radiation do not count as regimens
Patients previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer
Treatment with chemotherapy within  days of registration including subjects who received more than  chemotherapy regimens in the metastatic setting at any time prior to registration
Participants may have received - prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least  days prior to registration; participants should also be adequately recovered from acute toxicities of prior treatment
Patients must have NOT received more than two total prior lines of cytotoxic chemotherapy for management of recurrent or persistent disease, including re-treatment with initial chemotherapy regimens
Up to  prior chemotherapy regimens or metastatic disease
Received at least  prior chemotherapy-containing regimens.
Received fewer than  prior chemotherapy-containing regimens.
Subjects have received at least two standard chemotherapy regimens for which they would be considered eligible (at least one containing a -fluoropyrimidine), or systemic chemotherapy is not indicated in the setting of low volume metastatic disease
No more than  prior regimens of cytotoxic chemotherapy unless approved by the sponsor (Note: all platinum-containing regimens are not to be counted separately but are considered to be a single regimen for the purposes of this criterion)
Have previously received prior treatment with at least  but no more than  chemotherapy regimens in the metastatic setting.
Received  or more prior myelotoxic treatment regimens
Patient must have received =<  prior cytotoxic regimens in the metastatic setting
Patients receiving any other investigational agents and or more that two different chemotherapy regimens for treatment of metastatic disease
Patients with any prior chemotherapy regimens are eligible
Candidates for reduced intensity conditioning regimens
Patients may be enrolled in the study regardless of prior chemotherapy regimens
No more than two prior cytotoxic chemotherapeutic regimens for metastatic breast cancer; in addition, prior trastuzumab emtansine (TDM-, Kadcyla) is allowed
Received  or more prior myelotoxic treatment regimens
For both the extension and expansion cohorts, patients must have received or refused first line standard systemic therapy for their metastases (if applicable) and patients (pancreatic and esophageal cancers) must have received no more than two prior cytotoxic chemotherapy regimens in the last two years after standard therapy; patients (breast, ovarian and gastrointestinal cancers) must have received no more than three prior cytotoxic chemotherapy regimens in the last two years after standard therapy
Chemotherapy refractory large cell and high grade NHL (i.e. progressive disease after >  salvage regimens)
Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after >  salvage regimens)
Has received - prior chemotherapy regimens including taxanes in advanced setting Additional Inclusion Criteria for Dose Expansion Part Only:
Patients who have received more than  systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma\r\n* Note: prior perioperative chemotherapy is allowed and is not counted as a line of therapy
Must have received at least  prior regimens of standard chemotherapy for mCRC and must have been refractory to or failed (includes intolerance to) those regimens. Prior standard chemotherapy may not have included TAS- or regorafenib, but must have included agents as specified in the protocol.
Participants must have received prior platinum-based chemotherapy for management of\n             primary disease but must not have received more than  prior systemic cytotoxic\n             regimens.
Patients are allowed (but not required) to have up to two lines of prior chemotherapy regimens for metastatic disease
Patients must have received at least  chemotherapy regimens in the setting of metastatic disease
Prior chemotherapy with - regimens is allowed
Participants who have received oxaliplatin during prior systemic chemotherapy regimens are eligible for enrollment in this protocol
Participants who have received oxaliplatin during prior systemic chemotherapy regimens are eligible for enrollment in this protocol
Patients must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment
Is ineligible or inappropriate for other treatment regimens known to have effective potential
Disease progression after crizotinib and  or  prior regimens of chemotherapy in the metastatic disease setting.
Patients Must have completed  or  previous chemotherapy regimens.
Subjects must have received and have progressed, or are refractory to standard regimens
Has previously received at least  prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy.
At least one, but no more than three, prior chemotherapy regimens for MBC.
Received and experienced disease progression on, or following one or two prior chemotherapy regimens for advanced disease.
Received  or more prior myelotoxic treatment regimens
Patients will be ineligible if they have advanced myeloma refractory to salvage chemotherapy regimens
Patients must have received less than  prior chemotherapy regimens for progressive meningioma
Have received prior treatment with at least  chemotherapy regimens, of which at least  but no more than  have been administered in the metastatic setting.
No more than  prior chemotherapeutic regimens for metastatic disease
Prior chemotherapy regimens must include a platinum and/or a fluoropyrimidine component and must not include a taxane or antiangiogenic agent.
No more than three prior systemic chemotherapy regimens
>  prior chemotherapy regimens
Subject may have received ? prior regimens for the treatment of their metastatic disease.
Inclusion Criteria.\n\n          -  Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor\n             Receptor  Negative (HER-) breast cancer.\n\n          -  Recurrent, locally advanced, unresectable or metastatic breast cancer with disease\n             progression following anti-estrogen therapy.\n\n          -  Prior treatment with at least  chemotherapy regimens:\n\n               -  At least  of these regimens must have been administered in the metastatic\n                  setting.\n\n               -  At least  of these regimens must have contained a taxane.\n\n               -  No more than  prior chemotherapy regimens in the metastatic setting.\n\n          -  Have a performance status (PS) of  to  on the Eastern Cooperative Oncology Group\n             scale.\n\n          -  Have discontinued all previous therapies for cancer.\n\n          -  Have the presence of measureable disease as defined by Response Evaluation Criteria in\n             Solid Tumors Version ..\n\n        Exclusion Criteria:\n\n          -  Have either a history of central nervous system (CNS) metastasis or evidence of CNS\n             metastasis on the magnetic resonance image of brain obtained at baseline.\n\n          -  Received prior therapy with another cyclin-dependent kinases  and  (CDK/)\n             inhibitor.\n\n          -  Have received treatment with a drug that has not received regulatory approval for any\n             indication within  or  days of the initial dose of study drug.\n\n          -  Have had major surgery within  days of the initial dose of study drug.\n\n          -  Have a history of any other cancer (except non-melanoma skin cancer or carcinoma\n             in-situ of the cervix).
Patients with breast cancer may have received neoadjuvant or adjuvant chemotherapy and up to two prior chemotherapy regimens for metastatic or locally recurrent disease; subjects with ovarian cancer may have had two regimens for advanced or persistent disease
Patients must have had exposure to at least  and no more than  prior chemotherapy regimens for the treatment of metastatic breast cancer
Other chemotherapy regimens may have been administered between the time of progression on prior trastuzumab containing regimen and protocol therapy; no restriction on prior chemotherapy regimens for advanced stage disease
COHORT I: Patients must have received at least one and no more than two prior systemic therapy regimens; at least one of the regimens must have included pemetrexed and a platinum
Participants who have received more than two prior chemotherapy regimens for metastatic CRPC
More than two prior regimens for therapy of MM
More than  prior chemotherapy regimens; note: repeat use of regimens count as  prior regimen; switching front-line therapy regimens (for example, from intraperitoneal to intravenous therapy) for reasons other than progression will count as  prior therapy; bevacizumab and other targeted agents will count in the total number of prior regimens; vaccine therapies will not count in the total of prior therapies
Must have had at least  but no greater than  prior anti-myeloma regimens.
Experienced progression after one or more prior regimens of cytotoxic chemotherapy
Relapsed after ?  prior chemotherapy- or immunotherapy-based regimens for indolent NHL, or refractory to  prior chemotherapy and/ or immunotherapy-based regimens.
Patients with transformed indolent lymphoma must have received at least  prior chemotherapy- and/or immunotherapy-based regimens
Patients that have been treated with >  prior chemotherapy regimens
Patients with up to  prior chemotherapy regimens are eligible
Have received at least three prior chemotherapy regimens and have relapsed disease confirmed by radiologic assessment
Patients who have had  or more regimens containing cytotoxic chemotherapy for metastatic melanoma.
Patient must have received =<  prior cytotoxic regimens for metastatic breast cancer; this does not include cytotoxic regimens used in the adjuvant setting
Patients with recurrent or progressive disease after one or more regimens of pre-radiation chemotherapy
Prior treatment with fludarabine or alemtuzumab based regimens.
More than  prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]
More than  prior cytotoxic chemotherapy regimens
Women with TNBC who have received at least one but no more than two prior chemotherapy regimens for TNBC
Patients who have had more than  prior chemotherapy regimens
Patients may not have received more than  prior cytotoxic regimens
Prior chemotherapy regimens =< 
For Phase l, no more than  prior anticancer regimens (IL- or interferon do not count towards the total).
No more than  prior regimens for DLBCL.
More than  prior cytotoxic chemotherapy regimens for relapsed or metastatic disease
No more than  prior chemotherapy regimens.
Patients may not have received more than  prior regimens of therapy
Must have received the following treatment for glioblastoma: Prior treatment with radiotherapy and temozolomide; Note: A maximum of two prior chemotherapy/antibody regimens (including bevacizumab or other direct VEFG/VEGFR inhibitors) for recurrent disease are permitted.
Prior treatment with ?  prior chemotherapy-based or immunotherapy-based regimens for iNHL
Subject has received more than  prior cytotoxic agent-containing regimens.
Radiographic progression during treatment with erlotinib; prior chemotherapy regimens are permitted
Patients should have received a minimum of one, and up to five prior chemotherapy regimens
More than two regimens of systemic cytotoxic chemotherapy for recurrent or advanced NSCLC
Evidence of progressive disease during or following  or  prior chemotherapy regimens
No more than  prior regimens are allowed
Receipt of  or more prior cytotoxic chemotherapy regimens for advanced, recurrent, or metastatic endometrial cancer.
Subject previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer
Patients on the phase  portion of the study may not have more than  prior regimens for recurrent disease for glioblastoma/gliosarcoma. Patients on the phase  portion of the study may not have had more than  prior regimens.
Prior treatment with greater than (>) one cytotoxic chemotherapy regimens or experienced recurrent or progressive disease on > two endocrine therapies for MBC
Patient received at least  prior regimens for MM.
More than  prior cytotoxic chemotherapy regimens for recurrent or metastatic disease
More than one prior chemotherapy regimens
No more than two prior chemotherapy regimens for metastatic disease
Patients may not have received more than  prior cytotoxic regimens
Have received more than  prior CTX regimens
No more than  prior chemotherapy regimens
=<  prior chemotherapeutic regimens
Those receiving alternate regimens and those with other disease types
Have received prior chemotherapy regimens within  weeks of Day ;
Must be candidates for reduced-intensity conditioning regimens.
Patients must also receive a full myeloablative preparative regimen (patients treated with either total body irradiation (TBI)-based or high-dose chemotherapy only regimens are eligible other than high-dose busulfan containing regimens or regimens that include anti-thymocyte globulin or other T cell depleting antibodies)
Patients that are receiving or have received chemotherapy regimens are allowed
Two or more prior chemotherapy regimens for advanced disease
Zero or one prior chemotherapy regimens for metastatic disease
At least , but no more than , prior treatment regimens for MCL
Patients must have received less than three prior chemotherapy regimens for progressive meningioma
At least ?  prior treatment regimens for the underlying malignancy
Part C: must have previously received prior treatment with at least  but no more than  chemotherapy regimens in the metastatic setting
